Summary
Highlights
Dr. Rick Doblin discusses the current state of psychedelic research, noting its resurgence after decades of suppression due to the war on drugs. He explains that early research was stifled by policies like the Controlled Substances Act of 1970 and Nixon's war on drugs. However, a new group at the FDA in 1992, influenced by the AIDS movement, opened doors for beneficial psychedelic research. Non-profits have raised significant funds, and the pharmaceutical industry has invested billions, leading to a boom in studies globally. While spravado (a ketamine isomer) is the only FDA-approved psychedelic, several others like psilocybin, LSD, and 5-MeO-DMT are in advanced clinical trials. Doblin highlights the surprising bipartisan political support, particularly from Republicans, driven by the focus on veterans' mental health.
The discussion delves into how psychedelics, once associated with counterculture movements in the 1960s, are now gaining bipartisan acceptance. Doblin recounts how Nixon's administration criminalized psychedelics primarily to target political opponents, as revealed by John Erlickman. Historically, psychedelics were central to ancient spiritual practices, such as the Eleusinian Mysteries of ancient Greece, which influenced Western culture. These practices, often involving psychoactive substances, were later suppressed by institutions like the Catholic Church. Doblin emphasizes that the current shift is about removing psychedelics from cultural warfare and utilizing their therapeutic potential, especially for veterans and addressing the opioid crisis.
The conversation shifts to the opioid crisis, highlighting the role of pharmaceutical companies and the FDA in its development, particularly with the introduction of OxyContin. Doblin argues that the industry's focus on profit over patient well-being led to widespread addiction. Ibogaine, a psychedelic shown to alleviate opioid withdrawal and reset the brain, is presented as a potential solution. Despite its unique properties, ibogaine faces challenges with FDA approval due to its impact on heart rhythm. Doblin believes that with proper medical supervision, ibogaine can be administered safely, and advocates for a rational risk-benefit analysis given the high fatality risk of untreated opioid dependence. He notes that the public outcry and subsequent multi-billion dollar settlements against pharma companies for their role in the opioid crisis have created opportunities for funding ibogaine research, particularly in states like Texas.
Doblin stresses that the psychedelic experience is only one part of the therapeutic process; effective integration is crucial for lasting change. He likens it to drawing lessons from a profound experience and applying them to everyday life, ensuring that insights gained under the influence of psychedelics translate into sustainable personal growth. This process leverages the brain's neuroplasticity, which is significantly enhanced during and after psychedelic use. Doblin emphasizes that this neuroplastic state allows for the rewriting of traumatic memories and patterns, offering a powerful approach to healing that traditional medications, which often just manage symptoms, cannot. He expresses concern that for-profit psychedelic companies may de-emphasize therapy and integration, prioritizing drug sales over durable patient outcomes, a model he criticizes based on the limited long-term efficacy seen with Spravato when used without comprehensive therapy.
Doblin envisions a future where therapists are cross-trained in various psychedelics to customize treatments, and psychedelic clinics become widespread. He also discusses the growing influence of psychedelic churches, which offer alternative access to these substances under religious freedom laws. Doblin remains committed to his dual approach of working with the FDA to legitimize psychedelics as medicine while also advocating for drug policy reform that allows for regulated non-medical use, emphasizing education and peer support. He concludes by highlighting MAPS' global mission to expand access to MDMA therapy in a non-profit context, aiming to reduce the global burden of trauma and foster a consciousness shift towards compassion and mutual understanding. He proposes a 'gross national trauma measure' to track progress in healing societal wounds.